For further details see:
TherapeuticsMD, MoonLake top healthcare gainers; Outlook, Elevation Oncology lead losers' packFor further details see:
TherapeuticsMD, MoonLake top healthcare gainers; Outlook, Elevation Oncology lead losers' packMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...